Breast cancer is the most common form of cancer found in women across the globe. Although the rate of incidence of breast cancer has decreased in the past few years, reducing the mortality rate even further remains a big concern. Tamoxifen reduces the effects of the estrogen hormone in human body. The drug is used to treat/prevent breast cancer for both women and men. Tamoxifen can also be used to cure other kinds of cancers. Tamoxifen is also used to reduce the risk of breast cancer in women having high risk of developing breast cancer.
Geographically, the intraoperative imaging market is studied for the following regional markets:
Market size and forecast for these each regional and country level markets are presented in this study for the period 2013-2023. Market growth rates for the forecast period 2016-2023 are also included in this report, considering 2015 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as major market events, key breast cancer statistics and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global tamoxifen market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global clinical nutrition market. This report concludes with company profiles section that highlights major information about the key players engaged in tamoxifen market.
For the purpose of this study, the global tamoxifen market is categorized as follows:
North America is the largest regional market for tamoxifen drugs in 2015 and accounted for over 35%. High incidence of breast cancer, awareness about screening, prevention and management of breast cancer and favorable government policies are the prime factors allowing the growth of tamoxifen market in North America. The region is expected to retain its leas through the forecast period followed by Europe. The trends in European market are majorly determined by U.K., Germany, France and Belgium. Belgium is among the countries with the highest incidence of breast cancer, this market the country a promising market for tamoxifen drugs. U.K. and Germany are currently the largest country-level markets in Europe. Furthermore, Asia-Pacific and Rest of the World are estimated to register the fastest market growth during the forecast period due to growing recurrence of breast cancer and high prevalence of late-stage breast cancer detection. Rapid development of healthcare infrastructure is also for growth in these markets
